Omnicell, Inc. (NASDAQ:OMCL) Receives $37.83 Consensus PT from Analysts

Omnicell, Inc. (NASDAQ:OMCL) has been given an average recommendation of “Hold” by the seven ratings firms that are covering the company, MarketBeat.com reports. Four research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $37.83.

Several research analysts recently commented on the company. Bank of America boosted their price target on Omnicell from $34.00 to $44.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. Wells Fargo & Company increased their target price on Omnicell from $26.00 to $30.00 and gave the company an “equal weight” rating in a research note on Friday, August 2nd. StockNews.com downgraded shares of Omnicell from a “buy” rating to a “hold” rating in a research report on Thursday. Barclays raised shares of Omnicell from an “underweight” rating to an “equal weight” rating and upped their price target for the company from $26.00 to $39.00 in a report on Friday, August 2nd. Finally, JPMorgan Chase & Co. raised their price objective on shares of Omnicell from $26.00 to $37.00 and gave the stock a “neutral” rating in a report on Friday, August 23rd.

Omnicell Stock Up 2.8 %

Shares of Omnicell stock opened at $44.62 on Friday. The company has a fifty day moving average price of $39.21 and a 200 day moving average price of $32.31. The company has a current ratio of 2.45, a quick ratio of 2.22 and a debt-to-equity ratio of 0.47. Omnicell has a twelve month low of $25.12 and a twelve month high of $53.37. The stock has a market cap of $2.05 billion, a price-to-earnings ratio of -97.00, a price-to-earnings-growth ratio of 49.47 and a beta of 0.83.

Omnicell (NASDAQ:OMCL) last posted its earnings results on Thursday, August 1st. The company reported $0.51 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.14 by $0.37. The business had revenue of $276.80 million during the quarter, compared to analyst estimates of $254.41 million. Omnicell had a positive return on equity of 2.52% and a negative net margin of 1.92%. The company’s revenue for the quarter was down 7.4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.29 earnings per share. Equities research analysts forecast that Omnicell will post 0.64 earnings per share for the current fiscal year.

Institutional Trading of Omnicell

Institutional investors and hedge funds have recently bought and sold shares of the stock. Nisa Investment Advisors LLC boosted its holdings in shares of Omnicell by 248.8% in the second quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company’s stock worth $38,000 after buying an additional 1,000 shares during the period. EntryPoint Capital LLC grew its position in Omnicell by 121.2% during the 1st quarter. EntryPoint Capital LLC now owns 2,455 shares of the company’s stock worth $72,000 after purchasing an additional 1,345 shares in the last quarter. CWM LLC grew its position in Omnicell by 68.2% during the 2nd quarter. CWM LLC now owns 3,048 shares of the company’s stock worth $83,000 after purchasing an additional 1,236 shares in the last quarter. Benjamin Edwards Inc. raised its stake in Omnicell by 36.4% during the 1st quarter. Benjamin Edwards Inc. now owns 3,253 shares of the company’s stock valued at $95,000 after purchasing an additional 868 shares during the period. Finally, Headlands Technologies LLC purchased a new stake in shares of Omnicell in the second quarter valued at $104,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.